

EXHIBIT A: PARTIES' PROPOSED CONSTRUCTIONS AND SUPPORTING EVIDENCE

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
“vasopressin”	All asserted claims from all patents	Arginine vasopressin as described in SEQ. ID. No. 1 (<i>see, e.g.</i> , '239 patent, cols. 25-26).	<p><i>E.g.</i>, '239 Patent, 2:33-34, 3:1-2, Table 1 (vasopressin entry) (cols. 3-4); Table 3 (vasopressin entry) (cols. 19-20); Table 5 (vasopressin entry) (col. 22); 23:3-5; 24:15-19; 24:23-31; SEQ. NO 1 (cols. 25-26)</p> <p>'478 Patent, 2:45-46; 3:36-37; structure illustrated at cols. 1-2; Table 1 (vasopressin entry)(col. 3); Table 3 (vasopressin entry) (col. 18); Table 5 (vasopressin entry) (col. 21); 22:8-10; 23:20-24; 24:27-41; SEQ. NO 1 (cols. 25-26)</p> <p>'526 Patent, 2:66-67; 4:37-38; structure illustrated at cols. 3-4; Table 1 (vasopressin entry) (cols. 3-4); Table 3 (vasopressin entry) (cols. 55-56); Table 5 (vasopressin entry) (col. 59); 60:42-44; 61:54-</p>	Plain and ordinary meaning ¹	<p>Intrinsic Evidence</p> <p>'239 patent, claims 1 - 19 '478 patent, claims 1 - 11 '526 patent, claims 1 - 20 '209 patent, claims 1 - 13 '785 patent, claims 1 - 11 '223 patent, claims 1 - 18</p> <p>The specifications of the patents-in-suit, including the following passages:</p> <p><i>'239 patent</i>, col. 1, l. 18 - 28; col. 2, l. 3 - col. 3, l. 8; Table 1 (vasopressin entry) (cols. 3-4); Table 3 (vasopressin entry) (cols. 19-20); col. 19, l. 6 - 42; col. 22, l. 1 - 15; col. 23, l. 3-5; col. 24, l. 15 - 31; col. 25 - 26 (SEQ ID NO 1)</p>

¹ Sandoz reserves its right to further specify its proposed construction of “vasopressin,” if necessary, in light of further meet and confers between the parties as to the proper construction of that term.

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
			<p>58; 61:62-62:9; Tables 47-48 (vasopressin entries) (col. 100); Tables 50-51 (vasopressin entries) (col. 101); SEQ. NO 1 (cols. 103-104)</p> <p>'209 Patent, 2:66-67; 3:56-57; structure illustrated at cols. 3-4; Table 1 (vasopressin entry) (col. 3); Table 3 (vasopressin entry) (cols. 57-58); Table 5 (vasopressin entry) (col. 60); 61:3-5; 62:14-18; 62:22-36; Tables 47-48 (vasopressin entries) (cols. 101-102); Tables 50-51 (vasopressin entries) (col. 102); SEQ. NO 1 (cols. 107-110)</p> <p>'785 Patent, 2:66-67; 3:56-57; structure illustrated at cols. 3-4; Table 1 (vasopressin entry) (col. 2); Table 3 (vasopressin entry) (col. 57); Table 5 (vasopressin entry) (col. 59); 60:31-33; 61:45-49; 61:53-62:2; Tables 47-48 (vasopressin entries) (cols. 100-102); Tables 50-51 (vasopressin entries) (col. 101); SEQ. NO 1 (cols 105-108).</p>		<p><u>'478 patent</u>, col. 1, l. 16 - 25; col. 2, l. 18 - col. 3, l. 45; structure illustrated at cols. 1-2; Table 1 (vasopressin entry (col. 3); col. 18, l. 40 - col. 19, l. 14; col. 21, l. 5 - 19; col. 22, l. 8-10; col. 23, l. 20 - 41; col. 24, l. 27-41; col. 25 - 26 (SEQ ID NO 1)</p> <p><u>'526 patent</u>, col. 1, l. 15 - 22; col. 2, l. 35 - col. 4, l. 44; structure illustrated at cols. 3-4; Table 1 (vasopressin entry) (cols. 3-4); Table 3 (vasopressin entry) (cols. 55-56); col. 56, l. 57 - col. 57, l. 23; col. 59, l. 32 - 48; col. 60, l. 42-44; col. 61, l. 54 - col. 62, l. 9; Tables 50-51 (vasopressin entries) (col. 101); col. 100, l. 30 - col. 102, l. 13; col. 103 - 104 (SEQ ID NO 1)</p> <p><u>'785 patent</u>, col. 1, l. 13 - 21; col. 2, l. 36 - col. 3, l. 65; structure illustrated at cols. 3-4; Table 1 (vasopressin entry) (col. 2); col. 57, l. 4 - 42; col. 59, l. 22 - 37; col. 60, l. 31-33; col. 61, l. 45 - col. 62, l. 2; Tables 47-48 (vasopressin entries)</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
			<p>'223 Patent, 3:15-16; 4:46-47; structure illustrated at cols. 3-4; Table 1 (vasopressin entry) (cols. 3-4); Table 3 (vasopressin entry) (cols. 59-60); Table 5 (vasopressin entry) (col. 62); 63:21-23; 64:40-44; 64:48-63; Tables 47-48 (vasopressin entries) (cols. 103-104); Tables 50-51 (vasopressin entries) (cols. 104); 126:52-54; 128:7-11; 128:15-29; SEQ. NO 1 (cols. 129-130).</p> <p>USP38-NF33-Vasopressin Monograph (SAND-VASO00008517-8524)</p> <p>Par may additionally rely on expert opinion testimony to rebut any expert opinions proffered by Sandoz on this term.</p>		<p>(cols. 100-102); col. 100, l. 41 - col. 102, l. 48; col. 105 - 108 (SEQ ID NO 1), col. 113, l. 51 - col. 116, l. 22</p> <p><u>'209 patent</u>, col. 1, l. 19 - 25; col. 2, l. 37 - col. 3, l. 64; structure illustrated at cols. 3-4; Table 1 (vasopressin entry) (col. 3); Table 3 (vasopressin entry) (cols. 57-58); col. 56, l. 65 - col. 57, l. 38; col. 59, l. 60 - col. 60, l. 9; col. 61, l. 3-5; col. 62, l. 14 - 37; col. 101, l. 1 - col. 102, l. 67; col. 107 - 110 (SEQ ID NO 1), col. 115, l. 47 - col. 118, l. 23</p> <p><u>'223 patent</u>, col. 1, l. 16 - 22; col. 2, l. 56 - col. 4, l. 53; structure illustrated at cols. 3-4; Table 1 (vasopressin entry) (cols. 3-4); Table 3 (vasopressin entry) (cols. 59-60); col. 59, l. 36 - 67; col. 62, l. 10 - 27; Table 5 (vasopressin entry) (col. 62); col. 63, l. 21-23; col. 64, l. 40 - 63; col. 103, l. 1 - col. 104, l. 67; col. 108, l. 30 - col. 109, l. 52;</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>col. 126, l. 52-54; col. 128, l. 7 - 29; col. 129 - 130 (SEQ ID NO 1)</p> <p>Prosecution history of the '239 patent, including Application filed on May 20, 2015; Preliminary Amendment filed on June 3, 2015; Non-final Rejection dated June 5, 2015; Response after Non-final Rejection dated August 14, 2015; Affidavit filed August 14, 2015; Final Rejection filed October 21, 2015; Response to Final Rejection filed November 24, 2015; Non-Final Rejection dated January 11, 2016; Examiner Initiated Interview Summary dated March 17, 2016; Applicant-Initiated Interview Summary dated March 17, 2016; Response to Non-Final Rejection filed on March 17, 2016; Affidavit filed March 17, 2016; Final Rejection filed May 12, 2016; Applicant-Initiated Interview Summary dated September 9, 2016; Response after Final Rejection filed on November 3, 2016; Non-final Rejection dated November 22, 2016; Response to Non-Final</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>Rejection filed on May 22, 2017; Affidavit filed May 22, 2017; Notice of Allowance dated July 11, 2017; Issue Classification dated July 11, 2017</p> <p>Prosecution history of the '478 patent, including Application filed on May 20, 2015; Preliminary Amendment filed on June 3, 2015; Non-final Rejection dated June 8, 2015; Response after Non-final Rejection dated August 14, 2015; Affidavit filed on August 14, 2015; Final Rejection dated October 22, 2015; Response after Final Rejection dated January 22, 2016; Affidavit filed on January 22, 2016; Non-final Rejection dated February 2, 2016; Response after Non-Final Rejection dated March 31, 2016; Affidavit filed on March 31, 2016; Notice of Allowance dated May 4, 2016; Issue Classification dated May 4, 2016</p> <p>Prosecution history of the '526 patent, including Application filed</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>on October 10, 2016; Preliminary Amendment filed on October 10, 2016; Non-final Rejection dated February 22, 2017; Applicant-Initiated Interview Summary dated April 11, 2017; Response after Non-final Rejection dated May 2, 2017; Affidavit filed May 2, 2017 and signed on March 31, 2016; Affidavit filed May 2, 2017 and signed on May 1, 2017; Notice of Allowance dated May 12, 2017; Issue Classification dated May 12, 2016</p> <p>Prosecution history of the '785 patent, including Application filed on February 7, 2017; Preliminary Amendment dated February 7, 2017; Non-final Rejection dated March 29, 2017; Response after Non-final Rejection dated June 28, 2017; Applicant-Initiated Interview Summary dated July 3, 2017; Notice of Allowance dated July 20, 2017; Issue Classification dated July 20, 2017</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>Prosecution history of the '209 patent, including Application filed on February 7, 2017; Preliminary Amendment filed on February 7, 2017; Non-final Rejection dated March 29, 2017; Response after Non-final Rejection dated June 28, 2017; Applicant-Initiated Interview Summary dated July 3, 2017; Notice of Allowance dated July 11, 2017; Issue Classification dated July 11, 2017</p> <p>Prosecution history of the '223 patent, including Application filed on May 26, 2017; Preliminary Amendment filed on May 26, 2017; Non-final Rejection dated September 18, 2017; Response to Non-final Rejection dated November 27, 2017; Kannan Affidavit dated November 27, 2017; McIntyre Affidavit dated November 27, 2017; Notice of Allowance dated January 17, 2018; Issue Classification dated January 17, 2018</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>T. Treschan et al., The Vasopressin System Physiology and Clinical Strategies, <i>Anesthesiology</i> (2006) 105:599-612. (SAND-VASO00007208-7221)</p> <p>M.L. Buck, Low-dose Vasopressin Infusions for Vasodilatory Shock, Pediatric Pharmacotherapy (2003) 9(9): 1-4. (SAND-VASO00006921-6924)</p> <p>J.A. Russell, et al., Vasopressin Versus Norepinephrine Infusion in Patients with Septic Shock, <i>New Eng. J. Med.</i> (2008) 358:877-887 and Supplementary Appendix (SAND-VASO00007639-7667)</p> <p><u>Extrinsic Evidence:</u></p> <p>MPEP § 2422 (Nucleotide and/or Amino Acid Sequence Disclosures in Patent Applications)</p> <p>MPEP § 2424 (Requirements for Nucleotide and/or Amino Acid Sequences as Part of the Application Papers)</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>MPEP § 2429 (Helpful Hints for Compliance)</p> <p>K. Adamsons, Jr. et al., The Stability of Natural and Synthetic Neurohypophyseal Hormones in Vitro, <i>Endocrinology</i> (1958) 63(5):679-687 (SAND-VASO00006681-6689)</p> <p>K.A. Connors, et al., Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists 787-90 (2d ed. 1986) (SAND-VASO00006925-6931)</p> <p>J.A. Russell, Bench-to-bedside review: Vasopressin in the management of septic shock, <i>Critical Care</i> (2011) 15:226 (SAND-VASO00007179-7197)</p> <p>United States Pharmacopeial Convention, Inc., USP Certificate, Vasopressin, Lot F0G346 (2009) (SAND-VASO00007222-7223)</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>United States Pharmacopeial Convention, Inc., USP Certificate, Vasopressin, Lot G0J184 (2010) (SAND-VASO00007224-7225)</p> <p>United States Pharmacopeial Convention, Inc., USP Certificate, Vasopressin, Lot H0L444 (2013) (SAND-VASO00007228-7230)</p> <p>United States Pharmacopeial Convention, Inc., USP38-NF33 – Vasopressin (2014) (SAND-VASO00008517-8524)</p> <p>United States Pharmacopeial Convention, Inc., Vasopressin Injection (1990) (SAND-VASO00007728-7730)</p> <p>Sandoz may introduce testimony from one or more experts (e.g., Laird Forrest, Michael Maile) regarding the meaning of “vasopressin” in the relevant art and/or how a person of ordinary skill in the art would have understood this claim term.</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					Sandoz reserves the right to introduce rebuttal testimony from one or more experts (e.g., Laird Forrest, Michael Maile) in response to any expert testimony that Plaintiffs may introduce.
“administering to the human a unit dosage form”	'478 patent, claims 1-11 '209 Patent Claims 1-13	Ordinary meaning, no construction necessary. (<i>e.g.</i> , administering the claimed unit dosage form to the human in need of having his or her blood pressure increased)	<p><u>'478 Patent</u> Claim 1; 1:29-41; 5:45-47; 7:28-51; 8:23-27; 21:29-32, 21:37-49; 22:3-5; 23:20-24</p> <p><u>'239 Patent</u> Claims 1, 15, 1:30-46; 5:58-60; 7:45-8:2; 8:41-46; 22:18-67; 24:15-19, Table 6</p> <p><u>'209 Patent</u> Claim 1; 1:44-59; 6:23-26; 11:48-12:5; 12:45-46; 45:65-46:3; 60:21-23; 60:31-44; 60:65-67; 62:14-18; 101 (Table 47); 102 (Table 50)</p> <p><u>'526 Patent</u> Claim 1, 16; 1:40-57; 7:6-8; 11:47-12:4; 12:44-45; 36:48-45:59; 45:60-64; 59:59-61; 60:3-16; 60:27-39; 61:54-58; 62:10;</p>	“Administering to the human a unit dosage form having the properties recited in the claim”	<p>Intrinsic Evidence:</p> <p>'239 patent, claims 1 - 19 '478 patent, claims 1 - 11 '526 patent, claims 1 - 20 '209 patent, claims 1 - 13</p> <p>The specifications of the patents-in-suit, including the following passages:</p> <p><u>'478 patent</u>, col. 1, l. 28 - 41; col. 3, 1. 4 - 7; col. 5, l. 45 - 51; col. 7, 1. 28 - 51; col. 8, l. 23 - col. 9, l. 24; col. 12, l. 31 - 43; col. 21, l. 21 - col. 24, l. 23; col. 24, l. 25 - col. 25, l. 3; col. 33, l. 1 - col. 34, l. 24</p> <p><u>'526 patent</u>, col. 1, l. 40 - 59; col. 3, 1. 25 - 28; col. 6, l. 23 - 26; col. 7, 1. 6 - 8; col. 8, l. 21 - col. 9, l. 63; col. 11, l. 47 - col. 12, l. 5; col. 12, l. 44 - col. 13, l. 27; col. 13, l. 28 -</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
			<p>100 (Table 47); 101 (Table 50); Cols. 13-36.</p> <p><u>'223 Patent</u></p> <p>Claims 1, 11, 12; 1:38-54; 7:24-26; 12:48-13:5; 13:45-46; 46:65-47:3; 50:13-37; 55:30-56:28; 62:38-40; 62:48-61; 63:16-18; 64:40-44; 103 (Table 47); 104 (Table 50)</p> <p><u>'239 File History</u></p> <p>Applicant-Initiated Interview Summary (Appl. No. 14/717,977 ('239 Patent)) all pages (Sep. 9, 2016) – PAR-VASO-0008681-8686.</p> <p>Response to Final Office Action (Appl. No. 14/717,877 ('239 Patent)) 1-2, 4-5 (Nov. 3, 2016) – PAR-VASO-0008701-8705.</p> <p>Par may also rely on expert opinion testimony regarding the administration of vasopressin in clinical settings and how persons with knowledge thereof would understand the administration limitations of the patents-in-suit.</p>		<p>col. 47, l. 15; col. 50, l. 35 - 47; col. 59, l. 20 - col. 62, l. 59; col. 100, l. 30 - col. 102, l. 13; col. 102, l. 22 - 62; col. 109, l. 63 - col. 112, l. 31</p> <p><u>'209 patent</u>, col. 1, l. 42 - 59; col. 3, l. 25 - 28; col. 6, l. 23 - 30; col. 7, l. 61 - col. 9, l. 64; col. 11, l. 48 - col. 12, l. 5; col. 12, l. 45 - col. 13, l. 34; col. 13, l. 35 - col. 47, l. 20; col. 50, l. 44 - 56; col. 60, l. 12 - col. 63, l. 17; col. 101, l. 1 - col. 102, l. 67; col. 107, l. 44 - col. 108, l. 44; col. 115, l. 47 - col. 118, l. 23</p> <p><u>'239 patent</u>, col. 1, l. 30 - 46; col. 2, l. 38 - 41; col. 5, l. 58 - 64; col. 7, l. 45 - col. 8, l. 2; col. 8, l. 41 - 46; col. 8, l. 52 - col. 9, l. 61; col. 12, l. 55 - 67; col. 22, l. 18 - col. 25, l. 13; col. 25, l. 20 - col. 26, l. 28; col. 33, l. 30 - col. 35, l. 25</p> <p><u>'785 patent</u>, col. 1, l. 37 - 54; col. 3, l. 26 - 29; col. 6, l. 23 - 25; col. 7, l. 60 - col. 8, l. 40; col. 8, l. 65 - col. 9, l. 63; col. 11, l. 47 - 59;</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
			<p><i>See, e.g.</i>, Declarations of Zlatan Coralic, submitted in <i>Par et al. v. Eagle Pharmaceuticals Inc.</i>, 1:18-cv-00823-CFC, D.I. 64-2 at A-592-606, D.I. 64-3 at A-732-736 (D.Del.). Par may additionally rely on expert opinion testimony to rebut any expert opinions proffered by Sandoz on this term.</p> <p>Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. <i>Intensive Care Med</i> 2013;39:165-228, at pp. 179-183.</p> <p>Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i> 2010; 122:S729-67 at S736, S743.</p>		<p>col. 12, l. 44 - col. 13, l. 33; col. 13, l. 34 - col. 45, l. 62; col. 50, l. 44 - 56; col. 59, l. 33 - col. 62, l. 50; col. 105, l. 48 - col. 106, l. 48; col. 113, l. 50 - col. 116, l. 22</p> <p><u>'223 patent</u>, col. 1, l. 38 - 54; col. 3, l. 42 - 45; col. 7, l. 24 - 30; col. 8, l. 61 - col. 9, l. 41; col. 9, l. 66 - col. 10, l. 64; col. 12, l. 48 - col. 13, l. 5; col. 13, l. 45 - 46; col. 14, l. 35 - col. 48, l. 20; col. 50, l. 13 - 37; col. 52, l. 1 - 13; col. 55, l. 30 - col. 56, l. 28; col. 60, l. 13 - 37; col. 62, l. 30 - col. 66, l. 11; col. 103, l. 1 - col. 104, l. 67; col. 125, l. 20 - col. 129, l. 13; col. 129, l. 20 - col. 130, l. 28; col. 137, l. 30 - col. 140, l. 31</p> <p>Prosecution history of the '478 patent, including Application filed on May 20, 2015; Preliminary Amendment filed on June 3, 2015; Non-final Rejection dated June 8, 2015; Response after Non-final Rejection dated August 14, 2015; Affidavit filed on August 14, 2015; Final Rejection dated October 22,</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>2015; Response after Final Rejection dated January 22, 2016; Affidavit filed on January 22, 2016; Non-final Rejection dated February 2, 2016; Response after Non-Final Rejection dated March 31, 2016; Affidavit filed on March 31, 2016; Notice of Allowance dated May 4, 2016; Issue Classification dated May 4, 2016</p> <p>Prosecution history of the '209 patent, including Application filed on February 7, 2017; Preliminary Amendment filed on February 7, 2017; Non-final Rejection dated March 29, 2017; Response after Non-final Rejection dated June 28, 2017; Applicant-Initiated Interview Summary dated July 3, 2017; Notice of Allowance dated July 11, 2017; Issue Classification dated July 11, 2017</p> <p>Prosecution history of the '239 patent, including Application filed on May 20, 2015; Preliminary Amendment filed on June 3, 2015;</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					Non-final Rejection dated June 5, 2015; Response after Non-final Rejection dated August 14, 2015; Affidavit filed August 14, 2015; Final Rejection filed October 21, 2015; Response to Final Rejection filed November 24, 2015; Non-Final Rejection dated January 11, 2016; Examiner Initiated Interview Summary dated March 17, 2016; Applicant-Initiated Interview Summary dated March 17, 2016; Response to Non-Final Rejection filed on March 17, 2016; Affidavit filed March 17, 2016; Final Rejection filed May 12, 2016; Applicant-Initiated Interview Summary dated September 9, 2016; Response after Final Rejection filed on November 3, 2016; Non-final Rejection dated November 22, 2016; Response to Non-Final Rejection filed on May 22, 2017; Affidavit filed May 22, 2017; Notice of Allowance dated July 11, 2017; Issue Classification dated July 11, 2017

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>T. Treschan et al., The Vasopressin System Physiology and Clinical Strategies, <i>Anesthesiology</i> (2006) 105:599-612. (SAND-VASO00007208-7221)</p> <p>Pharmaceutical Partners of Canada Inc., Vasopressin Injection, USP, June 2009. (SAND-VASO00007111)</p> <p><u>Extrinsic Evidence:</u></p> <p>Sandoz may introduce testimony from one or more experts (e.g., Laird Forrest, Michael Maile) regarding peptide formulation, the administration of vasopressin in clinical settings, and/or how a person of ordinary skill in the art would have understood this claim term, namely that a person of ordinary skill would have understood the term to require “administering to the human a unit dosage form having the properties recited in the claim.”</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>Sandoz may introduce rebuttal testimony from one or more experts (e.g., Laird Forrest, Michael Maile) regarding peptide formulation, the administration of vasopressin in clinical settings, and/or how a person of ordinary skill in the art would have understood this claim term, namely that a person of ordinary skill would have not have understood the term in the manner proposed by Plaintiffs.</p> <p>R. P. Dellinger et al., Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. <i>Intensive Care Med</i> 2013;39:165-228, at pp. 179-183.</p> <p>R.W. Neumar, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i> 2010; 122:S729-67 at S736, S743.</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>CareFusion, User Manual, Alaris™ System, e.g., 2-108 to 2-114 (November 2014).</p> <p>Smiths Medical, Medfusion® Syringe Pump, Model 3500, Operator's Manual, e.g., 122-125, 128-130 (2013).</p> <p>E. Fulcher et al., Introduction to Intravenous Therapy for Health Professionals (1st ed. 2007)</p>
<p>“intravenously administering the pharmaceutical composition to the human”</p>	<p>'526 patent, claims 1-15, 20</p>	<p>Ordinary meaning, no construction necessary (e.g. administering the provided pharmaceutical composition into a vein of the human in need of having his or her blood</p>	<p><u>'478 Patent</u> Claim 1; 1:29-41; 5:45-47; 7:28-51; 8:23-27; 21:29-32, 21:37-49; 22:3-5; 23:20-24</p> <p><u>'239 Patent</u> Claims 1, 15, 1:30-46; 5:58-60; 7:45-8:2; 8:41-46; 22:18-67; 24:15-19, Table 6</p> <p><u>'209 Patent</u> Claim 1; 1:44-59; 6:23-26; 11:48-12:5; 12:45-46; 45:65-46:3; 60:21-23; 60:31-44; 60:65-67; 62:14-18; 101 (Table 47); 102 (Table 50)</p>	<p>“Intravenously administering the pharmaceutical composition having the properties recited in the claim to the human”</p>	<p>Intrinsic Evidence:</p> <p>'239 patent, claims 1 - 19 '478 patent, claims 1 - 11 '526 patent, claims 1 - 20 '209 patent, claims 1 - 13</p> <p>The specifications of the patents-in-suit, including the following passages:</p> <p><u>'478 patent</u>, col. 1, l. 28 - 41; col. 3, l. 4 - 7; col. 5, l. 45 - 51; col. 7, l. 28 - 51; col. 8, l. 23 - col. 9, l. 24; col. 12, l. 31 - 43; col. 21, l. 21 -</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
		pressure increased)	<p><u>'526 Patent</u> Claim 1, 16; 1:40-57; 7:6-8; 11:47-12:4; 12:44-45; 36:48-45:59; 45:60-64; 59:59-61; 60:3-16; 60:27-39; 61:54-58; 62:10; 100 (Table 47); 101 (Table 50); Cols. 13-36</p> <p><u>'223 Patent</u> Claims 1, 11, 12; 1:38-54; 7:24-26; 12:48-13:5; 13:45-46; 46:65-47:3; 50:13-37; 55:30-56:28; 62:38-40; 62:48-61; 63:16-18; 64:40-44; 103 (Table 47); 104 (Table 50)</p> <p><u>'239 File History</u> Applicant-Initiated Interview Summary (Appl. No. 14/717,977 ('239 Patent)) all pages (Sep. 9, 2016) – PAR-VASO-0008681-8686.</p> <p>Response to Final Office Action (Appl. No. 14/717,877 ('239 Patent)) 1-2, 4-5 (Nov. 3, 2016) – PAR-VASO-0008701-8705.</p> <p>Par may also rely on expert opinion testimony regarding the</p>		<p>col. 24, l. 23; col. 24, l. 25 - col. 25, l. 3; col. 33, l. 1 - col. 34, l. 24</p> <p><u>'526 patent</u>, col. 1, l. 40 - 59; col. 3, l. 25 - 28; col. 6, l. 23 - 26; col. 7, l. 6 - 8; col. 8, l. 21 - col. 9, l. 63; col. 11, l. 47 - col. 12, l. 5; col. 12, l. 44 - col. 13, l. 27; col. 13, l. 28 - col. 47, l. 15; col. 50, l. 35 - 47; col. 59, l. 20 - col. 62, l. 59; col. 100, l. 30 - - col. 102, l. 13; col. 102, l. 22 - 62; col. 109, l. 63 - col. 112, l. 31</p> <p><u>'209 patent</u>, col. 1, l. 42 - 59; col. 3, l. 25 - 28; col. 6, l. 23 - 30; col. 7, l. 61 - col. 9, l. 64; col. 11, l. 48 - col. 12, l. 5; col. 12, l. 45 - col. 13, l. 34; col. 13, l. 35 - col. 47, l. 20; col. 50, l. 44 - 56; col. 60, l. 12 - col. 63, l. 17; col. 101, l. 1 - col. 102, l. 67; col. 107, l. 44 - col. 108, l. 44; col. 115, l. 47 - col. 118, l. 23</p> <p><u>'239 patent</u>, col. 1, l. 30 - 46; col. 2, l. 38 - 41; col. 5, l. 58 - 64; col. 7, l. 45 - col. 8, l. 2; col. 8, l. 41 - 46; col. 8, l. 52 - col. 9, l. 61; col. 12,</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
			<p>administration of vasopressin in clinical settings and how persons with knowledge thereof would understand the administration limitations of the patents-in-suit. <i>See, e.g.</i>, Declarations of Zlatan Coralic, submitted in <i>Par et al. v. Eagle Pharmaceuticals Inc.</i>, 1:18-cv-00823-CFC, D.I. 64-2 at A-592-606, D.I. 64-3 at A-732-736 (D.Del.). Par may additionally rely on expert opinion testimony to rebut any expert opinions proffered by Sandoz on this term.</p> <p>Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. <i>Intensive Care Med</i> 2013;39:165-228, at pp. 179-183.</p> <p>Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency</p>		<p>1. 55 - 67; col. 22, l. 18 - col. 25, l. 13; col. 25, l. 20 - col. 26, l. 28; col. 33, l. 30 - col. 35, l. 25</p> <p><u>'785 patent</u>, col. 1, l. 37 - 54; col. 3, l. 26 - 29; col. 6, l. 23 - 25; col. 7, l. 60 - col. 8, l. 40; col. 8, l. 65 - col. 9, l. 63; col. 11, l. 47 - 59; col. 12, l. 44 - col. 13, l. 33; col. 13, l. 34 - col. 45, l. 62; col. 50, l. 44 - 56; col. 59, l. 33 - col. 62, l. 50; col. 105, l. 48 - col. 106, l. 48; col. 113, l. 50 - col. 116, l. 22</p> <p><u>'223 patent</u>, col. 1, l. 38 - 54; col. 3, l. 42 - 45; col. 7, l. 24 - 30; col. 8, l. 61 - col. 9, l. 41; col. 9, l. 66 - col. 10, l. 64; col. 12, l. 48 - col. 13, l. 5; col. 13, l. 45 - 46; col. 14, l. 35 - col. 48, l. 20; col. 50, l. 13 - 37; col. 52, l. 1 - 13; col. 55, l. 30 - col. 56, l. 28; col. 60, l. 13 - 37; col. 62, l. 30 - col. 66, l. 11; col. 103, l. 1 - col. 104, l. 67; col. 125, l. 20 - col. 129, l. 13; col. 129, l. 20 - col. 130, l. 28; col. 137, l. 30 - col. 140, l. 31</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
			Cardiovascular Care. Circulation 2010; 122:S729-67 at S736, S743.		<p>Prosecution history of the '526 patent, including Application filed on October 10, 2016; Preliminary Amendment filed on October 10, 2016; Non-final Rejection dated February 22, 2017; Applicant-Initiated Interview Summary dated April 11, 2017; Response after Non-final Rejection dated May 2, 2017; Affidavit filed May 2, 2017 and signed on March 31, 2016; Affidavit filed May 2, 2017 and signed on May 1, 2017; Notice of Allowance dated May 12, 2017; Issue Classification dated May 12, 2016</p> <p>Prosecution history of the '239 patent, including Application filed on May 20, 2015; Preliminary Amendment filed on June 3, 2015; Non-final Rejection dated June 5, 2015; Response after Non-final Rejection dated August 14, 2015; Affidavit filed August 14, 2015; Final Rejection filed October 21, 2015; Response to Final Rejection filed November 24, 2015; Non-Final Rejection dated January 11,</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>2016; Examiner Initiated Interview Summary dated March 17, 2016; Applicant-Initiated Interview Summary dated March 17, 2016; Response to Non-Final Rejection filed on March 17, 2016; Affidavit filed March 17, 2016; Final Rejection filed May 12, 2016; Applicant-Initiated Interview Summary dated September 9, 2016; Response after Final Rejection filed on November 3, 2016; Non-final Rejection dated November 22, 2016; Response to Non-Final Rejection filed on May 22, 2017; Affidavit filed May 22, 2017; Notice of Allowance dated July 11, 2017; Issue Classification dated July 11, 2017</p> <p>Prosecution history of the '223 patent, including Application filed on May 26, 2017; Preliminary Amendment filed on May 26, 2017; Non-final Rejection dated September 18, 2017; Response to Non-final Rejection dated November 27, 2017; Kannan Affidavit dated November 27,</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>2017; McIntyre Affidavit dated November 27, 2017; Notice of Allowance dated January 17, 2018; Issue Classification dated January 17, 2018</p> <p>T. Treschan et al., The Vasopressin System Physiology and Clinical Strategies, <i>Anesthesiology</i> (2006) 105:599-612. (SAND-VASO00007208-7221)</p> <p>Pharmaceutical Partners of Canada Inc., Vasopressin Injection, USP, June 2009. (SAND-VASO00007111)</p> <p><u>Extrinsic Evidence:</u></p> <p>Sandoz may introduce testimony from one or more experts (e.g., Laird Forrest, Michael Maile) regarding peptide formulation, the administration of vasopressin in clinical settings, and/or how a person of ordinary skill in the art would have understood this claim term, namely that a person of ordinary skill would have</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>understood the term to require “intravenously administering the pharmaceutical composition having the properties recited in the claim to the human.”</p> <p>Sandoz may introduce rebuttal testimony from one or more experts (e.g., Laird Forrest, Michael Maile) regarding peptide formulation, the administration of vasopressin in clinical settings, and/or how a person of ordinary skill in the art would have understood this claim term, namely that a person of ordinary skill would have not have understood the term in the manner proposed by Plaintiffs.</p> <p>R. P. Dellinger et al., Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228, at pp. 179-183.</p> <p>R.W. Neumar, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i> 2010; 122:S729-67 at S736, S743.</p> <p>CareFusion, User Manual, Alaris™ System, e.g., 2-108 to 2-114 (November 2014).</p> <p>Smiths Medical, Medfusion® Syringe Pump, Model 3500, Operator's Manual, e.g., 122-125, 128-130 (2013).</p> <p>E. Fulcher et al., Introduction to Intravenous Therapy for Health Professionals (1st ed. 2007)</p>
“administering the diluted unit dosage form to the human by intravenous administration”	'239 patent, claims 1-19	Ordinary meaning, no construction necessary <i>(e.g.</i> administering the provided unit dosage form in its	<p><u>'478 Patent</u> Claim 1; 1:29-41; 5:45-47; 7:28-51; 8:23-27; 21:29-32, 21:37-49; 22:3-5; 23:20-24</p> <p><u>'239 Patent</u> Claims 1, 15, 1:30-46; 5:58-60; 7:45-8:2; 8:41-46; 22:18-67; 24:15-19, Table 6</p>	“Administering the diluted unit dosage form having the properties recited in the claim to the human by intravenous administration”	<p>Intrinsic Evidence:</p> <p>'239 patent, claims 1 - 19 '478 patent, claims 1 - 11 '526 patent, claims 1 - 20 '209 patent, claims 1 - 13</p> <p>The specifications of the patents-in-suit, including the following passages:</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
		diluted form into a vein of the human in need of having his or her blood pressure increased)	<p><u>'209 Patent</u></p> <p>Claim 1; 1:44-59; 6:23-26; 11:48-12:5; 12:45-46; 45:65-46:3; 60:21-23; 60:31-44; 60:65-67; 62:14-18; 101 (Table 47); 102 (Table 50)</p> <p><u>'526 Patent</u></p> <p>Claim 1, 16; 1:40-57; 7:6-8; 11:47-12:4; 12:44-45; 36:48-45:59; 45:60-64; 59:59-61; 60:3-16; 60:27-39; 61:54-58; 62:10; 100 (Table 47); 101 (Table 50); Cols. 13-36</p> <p><u>'223 Patent</u></p> <p>Claims 1, 11, 12; 1:38-54; 7:24-26; 12:48-13:5; 13:45-46; 46:65-47:3; 50:13-37; 55:30-56:28; 62:38-40; 62:48-61; 63:16-18; 64:40-44; 103 (Table 47); 104 (Table 50)</p> <p><u>'239 File History</u></p> <p>Applicant-Initiated Interview Summary (Appl. No. 14/717,977 ('239 Patent)) all pages (Sep. 9, 2016) – PAR-VASO-0008681-8686.</p>		<p><u>'478 patent</u>, col. 1, l. 28 - 41; col. 3, l. 4 - 7; col. 5, l. 45 - 51; col. 7, l. 28 - 51; col. 8, l. 23 - col. 9, l. 24; col. 12, l. 31 - 43; col. 21, l. 21 - col. 24, l. 23; col. 24, l. 25 - col. 25, l. 3; col. 33, l. 1 - col. 34, l. 24</p> <p><u>'526 patent</u>, col. 1, l. 40 - 59; col. 3, l. 25 - 28; col. 6, l. 23 - 26; col. 7, l. 6 - 8; col. 8, l. 21 - col. 9, l. 63; col. 11, l. 47 - col. 12, l. 5; col. 12, l. 44 - col. 13, l. 27; col. 13, l. 28 - col. 47, l. 15; col. 50, l. 35 - 47; col. 59, l. 57 - col. 62, l. 59; col. 100, l. 30 - col. 102, l. 13; col. 102, l. 22 - 62; col. 109, l. 63 - col. 112, l. 31</p> <p><u>'209 patent</u>, col. 1, l. 42 - 59; col. 3, l. 25 - 28; col. 6, l. 23 - 30; col. 7, l. 61 - col. 9, l. 64; col. 11, l. 48 - col. 12, l. 5; col. 12, l. 45 - col. 13, l. 34; col. 13, l. 35 - col. 47, l. 20; col. 50, l. 44 - 56; col. 60, l. 12 - col. 63, l. 17; col. 101, l. 1 - col. 102, l. 67; col. 107, l. 44 - col. 108, l. 44; col. 115, l. 47 - col. 118, l. 23</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
			<p>Response to Final Office Action (Appl. No. 14/717,877 ('239 Patent)) 1-2, 4-5 (Nov. 3, 2016)—PAR-VASO-0008701-8705.</p> <p>Par may also rely on expert opinion testimony regarding the administration of vasopressin in clinical settings and how persons with knowledge thereof would understand the administration limitations of the patents-in-suit. <i>See, e.g.</i>, Declarations of Zlatan Coralic, submitted in <i>Par et al. v. Eagle Pharmaceuticals Inc.</i>, 1:18-cv-00823-CFC, D.I. 64-2 at A-592-606, D.I. 64-3 at A-732-736 (D.Del.). Par may additionally rely on expert opinion testimony to rebut any expert opinions proffered by Sandoz on this term.</p> <p>Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. <i>Intensive Care Med</i> 2013;39:165-228, at pp. 179-183.</p>		<p>'239 patent, col. 1, l. 30 - 46; col. 2, 1. 38 - 41; col. 5, l. 58 - 64; col. 7, 1. 45 - col. 8, l. 2; col. 8, l. 41 - 46; col. 8, l. 52 - col. 9, l. 61; col. 12, 1. 55 - 67; col. 22, l. 18 - col. 25, l. 13; col. 25, l. 20 - col. 26, l. 28; col. 33, l. 30 - col. 35, l. 25</p> <p>'785 patent, col. 1, l. 37 - 54; col. 3, 1. 26 - 29; col. 6, l. 23 - 25; col. 7, 1. 60 - col. 8, l. 40; col. 8, l. 65 - col. 9, l. 63; col. 11, l. 47 - 59; col. 12, l. 44 - col. 13, l. 33; col. 13, l. 34 - col. 45, l. 62; col. 50, l. 44 - 56; col. 59, l. 33 - col. 62, l. 50; col. 105, l. 48 - col. 106, l. 48; col. 113, l. 50 - col. 116, l. 22</p> <p>'223 patent, col. 1, l. 38 - 54; col. 3, 1. 42 - 45; col. 7, l. 24 - 30; col. 8, l. 61 - col. 9, l. 41; col. 9, l. 66 - col. 10, l. 64; col. 12, l. 48 - col. 13, l. 5; col. 13, l. 45 - 46; col. 14, l. 35 - col. 48, l. 20; col. 50, l. 13 - 37; col. 52, l. 1 - 13; col. 55, l. 30 - col. 56, l. 28; col. 60, l. 13 - 37; col. 62, l. 30 - col. 66, l. 11; col. 103, l. 1 - col. 104, l. 67;</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
			Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S729-67 at S736, S743.		col. 125, l. 20 - col. 129, l. 13; col. 129, l. 20 - col. 130, l. 28; col. 137, l. 30 - col. 140, l. 31 Prosecution history of the '239 patent, including Application filed on May 20, 2015; Preliminary Amendment filed on June 3, 2015; Non-final Rejection dated June 5, 2015; Response after Non-final Rejection dated August 14, 2015; Affidavit filed August 14, 2015; Final Rejection filed October 21, 2015; Response to Final Rejection filed November 24, 2015; Non-Final Rejection dated January 11, 2016; Examiner Initiated Interview Summary dated March 17, 2016; Applicant-Initiated Interview Summary dated March 17, 2016; Response to Non-Final Rejection filed on March 17, 2016; Affidavit filed March 17, 2016; Final Rejection filed May 12, 2016; Applicant-Initiated Interview Summary dated September 9, 2016; Response after Final Rejection filed on November 3, 2016; Non-final Rejection dated November 22,

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>2016; Response to Non-Final Rejection filed on May 22, 2017; Affidavit filed May 22, 2017; Notice of Allowance dated July 11, 2017; Issue Classification dated July 11, 2017</p> <p>T. Treschan et al., The Vasopressin System Physiology and Clinical Strategies, <i>Anesthesiology</i> (2006) 105:599-612. (SAND-VASO00007208-7221)</p> <p>Pharmaceutical Partners of Canada Inc., Vasopressin Injection, USP, June 2009. (SAND-VASO00007111)</p> <p><u>Extrinsic Evidence:</u></p> <p>Sandoz may introduce testimony from one or more experts (e.g., Laird Forrest, Michael Maile) regarding peptide formulation, the administration of vasopressin in clinical settings, and/or how a person of ordinary skill in the art would have understood this claim term, namely that a person of</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>ordinary skill would have understood the term to require “administering the diluted unit dosage form having the properties recited in the claim to the human by intravenous administration.”</p> <p>Sandoz may introduce rebuttal testimony from one or more experts (e.g., Laird Forrest, Michael Maile) regarding peptide formulation, the administration of vasopressin in clinical settings, and/or how a person of ordinary skill in the art would have understood this claim term, namely that a person of ordinary skill would have not have understood the term in the manner proposed by Plaintiffs.</p> <p>R. P. Dellinger et al., Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228, at pp. 179-183.</p> <p>R.W. Neumar, et al. Part 8: adult advanced cardiovascular life</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i> 2010; 122:S729-67 at S736, S743.</p> <p>CareFusion, User Manual, Alaris™ System, e.g., 2-108 to 2-114 (November 2014).</p> <p>Smiths Medical, Medfusion® Syringe Pump, Model 3500, Operator's Manual, e.g., 122-125, 128-130 (2013).</p> <p>E. Fulcher et al., Introduction to Intravenous Therapy for Health Professionals (1st ed. 2007)</p>
“intravenously administering the portion[/second portion] of the pharmaceutical composition to the human”	'223 patent, claims 1-11	Ordinary meaning, no construction necessary <i>(e.g.</i> administering the recited portion of the	<p><u>'223 Patent</u> Claims 1, 11, 12; 1:38- 54; 7:24-26; 12:48-13:5; 13:45-46; 46:65-47:3; 50:13-37; 55:30-56:28; 62:38-40; 62:48-61; 63:16-18; 64:40-44; 103 (Table 47); 104 (Table 50)</p> <p><u>'478 Patent</u></p>	“Intravenously administering the portion[/second portion] of the pharmaceutical composition having the properties recited	<p>Intrinsic Evidence:</p> <p>'239 patent, claims 1 - 19 '478 patent, claims 1 - 11 '526 patent, claims 1 - 20 '209 patent, claims 1 - 13 '223 patent, claims 1 - 18</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
		provided pharmaceutical composition into a vein of the human in need of having his or her blood pressure increased)	<p>Claim 1; 1:29-41; 5:45-47; 7:28-51; 8:23-27; 21:29-32, 21:37-49; 22:3-5; 23:20-24</p> <p><u>'239 Patent</u> Claims 1, 15, 1:30-46; 5:58-60; 7:45-8:2; 8:41-46; 22:18-67; 24:15-19, Table 6</p> <p><u>'209 Patent</u> Claim 1; 1:44-59; 6:23-26; 11:48-12:5; 12:45-46; 45:65-46:3; 60:21-23; 60:31-44; 60:65-67; 62:14-18; 101 (Table 47); 102 (Table 50)</p> <p><u>'526 Patent</u> Claim 1, 16; 1:40-57; 7:6-8; 11:47-12:4; 12:44-45; 36:48-45:59; 45:60-64; 59:59-61; 60:3-16; 60:27-39; 61:54-58; 62:10; 100 (Table 47); 101 (Table 50); Cols. 13-36.</p> <p><u>'239 File History</u> Applicant-Initiated Interview Summary (Appl. No. 14/717,977 ('239 Patent)) all pages (Sep. 9, 2016) – PAR-VASO-0008681-8686.</p>	in the claim to the human”	<p>The specifications of the patents-in-suit, including the following passages:</p> <p><u>'478 patent</u>, col. 1, l. 28 - 41; col. 3, l. 4 - 7; col. 5, l. 45 - 51; col. 7, l. 28 - 51; col. 8, l. 23 - col. 9, l. 24; col. 12, l. 31 - 43; col. 21, l. 21 - col. 24, l. 23; col. 24, l. 25 - col. 25, l. 3; col. 33, l. 1 - col. 34, l. 24</p> <p><u>'526 patent</u>, col. 1, l. 40 - 59; col. 3, l. 25 - 28; col. 6, l. 23 - 26; col. 7, l. 6 - 8; col. 8, l. 21 - col. 9, l. 63; col. 11, l. 47 - col. 12, l. 5; col. 12, l. 44 - col. 13, l. 27; col. 13, l. 28 - col. 47, l. 15; col. 59, l. 57 - col. 62, l. 59; col. 100, l. 30 - col. 102, l. 13; col. 102, l. 22 - 62; col. 109, l. 63 - col. 112, l. 31</p> <p><u>'209 patent</u>, col. 1, l. 42 - 59; col. 3, l. 25 - 28; col. 6, l. 23 - 30; col. 7, l. 61 - col. 9, l. 64; col. 11, l. 48 - col. 12, l. 5; col. 12, l. 45 - col. 13, l. 34; col. 13, l. 35 - col. 47, l. 20; col. 50, l. 44 - 56; col. 60, l. 12 - col. 63, l. 17; col. 101, l. 1 - col. 102, l. 67; col. 107, l. 44 -</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
			<p>Response to Final Office Action (Appl. No. 14/717,877 ('239 Patent)) 1-2, 4-5 (Nov. 3, 2016)—PAR-VASO-0008701-8705.</p> <p>Par may also rely on expert opinion testimony regarding the administration of vasopressin in clinical settings and how persons with knowledge thereof would understand the administration limitations of the patents-in-suit. <i>See, e.g.</i>, Declarations of Zlatan Coralic, submitted in <i>Par et al. v. Eagle Pharmaceuticals Inc.</i>, 1:18-cv-00823-CFC, D.I. 64-2 at A-592-606, D.I. 64-3 at A-732-736 (D.Del.). Par may additionally rely on expert opinion testimony to rebut any expert opinions proffered by Sandoz on this term.</p> <p>Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. <i>Intensive Care Med</i> 2013;39:165-228, at pp. 179-183.</p>		<p>col. 108, l. 44; col. 115, l. 47 - col. 118, l. 23</p> <p><u>'239 patent</u>, col. 1, l. 30 - 46; col. 2, l. 38 - 41; col. 5, l. 58 - 64; col. 7, l. 45 - col. 8, l. 2; col. 8, l. 41 - 46; col. 8, l. 52 - col. 9, l. 61; col. 12, l. 55 - 67; col. 22, l. 18 - col. 25, l. 13; col. 25, l. 20 - col. 26, l. 28; col. 33, l. 30 - col. 35, l. 25</p> <p><u>'785 patent</u>, col. 1, l. 37 - 54; col. 3, l. 26 - 29; col. 6, l. 23 - 25; col. 7, l. 60 - col. 8, l. 40; col. 8, l. 65 - col. 9, l. 63; col. 11, l. 47 - 59; col. 12, l. 44 - col. 13, l. 33; col. 13, l. 34 - col. 45, l. 62; col. 50, l. 44 - 56; col. 59, l. 33 - col. 62, l. 50; col. 105, l. 48 - col. 106, l. 48; col. 113, l. 50 - col. 116, l. 22</p> <p><u>'223 patent</u>, col. 1, l. 38 - 54; col. 3, l. 42 - 45; col. 7, l. 24 - 30; col. 8, l. 61 - col. 9, l. 41; col. 9, l. 66 - col. 10, l. 64; col. 12, l. 48 - col. 13, l. 5; col. 13, l. 45 - 46; col. 14, l. 35 - col. 48, l. 20; col. 50, l. 13 - 37; col. 52, l. 1 - 13; col. 55, l. 30 - col. 56, l. 28; col. 60, l. 13 - 37;</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
			Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S729-67 at S736, S743.		<p>col. 62, l. 30 - col. 66, l. 11; col. 103, l. 1 - col. 104, l. 67; col. 125, l. 20 - col. 129, l. 13; col. 129, l. 20 - col. 130, l. 28; col. 137, l. 30 - col. 140, l. 31</p> <p>Prosecution history of the '223 patent, including Application filed on May 26, 2017; Preliminary Amendment filed on May 26, 2017; Non-final Rejection dated September 18, 2017; Response to Non-final Rejection dated November 27, 2017; Kannan Affidavit dated November 27, 2017; McIntyre Affidavit dated November 27, 2017; Notice of Allowance dated January 17, 2018; Issue Classification dated January 17, 2018</p> <p>Prosecution history of the '239 patent, including Application filed on May 20, 2015; Preliminary Amendment filed on June 3, 2015; Non-final Rejection dated June 5, 2015; Response after Non-final Rejection dated August 14, 2015; Affidavit filed August 14, 2015;</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>Final Rejection filed October 21, 2015; Response to Final Rejection filed November 24, 2015; Non-Final Rejection dated January 11, 2016; Examiner Initiated Interview Summary dated March 17, 2016; Applicant-Initiated Interview Summary dated March 17, 2016; Response to Non-Final Rejection filed on March 17, 2016; Affidavit filed March 17, 2016; Final Rejection filed May 12, 2016; Applicant-Initiated Interview Summary dated September 9, 2016; Response after Final Rejection filed on November 3, 2016; Non-final Rejection dated November 22, 2016; Response to Non-Final Rejection filed on May 22, 2017; Affidavit filed May 22, 2017; Notice of Allowance dated July 11, 2017; Issue Classification dated July 11, 2017</p> <p>T. Treschan et al., The Vasopressin System Physiology and Clinical Strategies, <i>Anesthesiology</i> (2006) 105:599-612. (SAND-VASO00007208-7221)</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>Pharmaceutical Partners of Canada Inc., Vasopressin Injection, USP, June 2009. (SAND-VASO00007111)</p> <p><u>Extrinsic Evidence:</u></p> <p>Sandoz may introduce testimony from one or more experts (e.g., Laird Forrest, Michael Maile) regarding peptide formulation, the administration of vasopressin in clinical settings, and/or how a person of ordinary skill in the art would have understood this claim term, namely that a person of ordinary skill would have understood the term to require “intravenously administering the portion[/second portion] of the pharmaceutical composition having the properties recited in the claim to the human.”</p> <p>Sandoz may introduce rebuttal testimony from one or more experts (e.g., Laird Forrest, Michael Maile) regarding peptide formulation, the</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>administration of vasopressin in clinical settings, and/or how a person of ordinary skill in the art would have understood this claim term, namely that a person of ordinary skill would have not have understood the term in the manner proposed by Plaintiffs.</p> <p>R. P. Dellinger et al., Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. <i>Intensive Care Med</i> 2013;39:165-228, at pp. 179-183.</p> <p>R.W. Neumar, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i> 2010; 122:S729-67 at S736, S743.</p> <p>CareFusion, User Manual, Alaris™ System, e.g., 2-108 to 2-114 (November 2014).</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>Smiths Medical, Medfusion® Syringe Pump, Model 3500, Operator's Manual, e.g., 122-125, 128-130 (2013).</p> <p>E. Fulcher et al., Introduction to Intravenous Therapy for Health Professionals (1st ed. 2007)</p>
"wherein the impurities are determined based on"	<p>'209 patent, claim 11</p> <p>'785 patent, claim 2</p>	<p>Ordinary meaning, no construction necessary (e.g., wherein any determination as to whether the pharmaceutical composition includes the specified impurities is to be made via the recited procedure)</p>	<p>E.g., '209 Patent claim 1, 11; 52:16-53:55; 54:4-57:40 (Example 1). '785 Patent claim 1, 2; 52:16-53:57; 54:9-57:43 (Example 1). Par may additionally rely on expert opinion testimony to rebut any expert opinions proffered by Sandoz on this term.</p>	<p>This phrase requires a step of determining the impurities based on the HPLC method recited in the claim</p>	<p><u>Intrinsic Evidence:</u> '209 patent, claims 1, 11 '785 patent, claims 1, 2 The specifications of the patents-in-suit, including the following passages: '478 patent, col. 2, l. 3 - 4; col. 6, l. 53 - col. 7, l. 21; col. 7, l. 53 - col. 8, l. 22; col. 14, l. 50 - col. 15, l. 25; col. 15, l. 41 - col. 19, l. 15; col. 19, l. 19 - 28; col. 19, l. 30 - 54; col. 20, l. 9 - 19; col. 20, l. 21 - col. 21, l. 3 '526 patent, col. 2, l. 10 - 26; col. 52, l. 56 - col. 53, l. 9; col. 53, l. 50 - col. 57, l. 25; col. 57, l. 25 -</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>38; col. 57, l. 40 - 67; col. 58, l. 45 - col. 59, l. 31; col. 59, l. 32 - 50; col. 63, l. 2 - col. 70, l. 20; col. 97, l. 1 - col. 98, l. 47; col. 98, l. 49 - col. 99, l. 30; col. 99, l. 31 - col. 100, l. 29</p> <p><u>'209 patent</u>, col. 1, l. 60 - col. 2, l. 33; col. 2, l. 66 - col. 4, l. 39; col. 8, l. 42 - 65; col. 9, l. 13 - 64; col. 10, l. 21 - col. 11, l. 33; col. 12, l. 7 - 43; col. 52, l. 16 - col. 53, l. 55; col. 54, l. 4 - col. 57, l. 40; col. 57, l. 40 - 55; col. 57, l. 56 - col. 58, l. 55; col. 59, l. 10 - 59; col. 63, l. 20 - col. 97, l. 40; col. 97, l. 41 - col. 99, l. 16; col. 99, l. 16 - 60; col. 99, l. 61 - col. 100, l. 67; col. 103, l. 3 - col. 107, l. 39; col. 115, l. 48 - 64; col. 117, l. 11 - col. 118, l. 19; Figs. 1-19.</p> <p><u>'239 patent</u>, col. 15, l. 10 - 42; col. 16, l. 9 - col. 19, l. 44; col. 19, l. 45 - 57; col. 19, l. 60 - col. 20, l. 52; col. 21, l. 4 - 67</p> <p><u>'785 patent</u>, col. 1, l. 58 - col. 2, l. 31; col. 2, l. 66 - col. 4, l. 40;</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>col. 8, l. 41 - 64; col. 9, l. 12 - 63; col. 10, l. 20 - col. 11, l. 32; col. 12, l. 6 - 42; col. 52, l. 16 - col. 53, l. 57; col. 54, l. 9 - col. 57, l. 43; col. 57, l. 44 - 56; col. 57, l. 60 - col. 58, l. 16; col. 58, l. 40 - col. 59, l. 21; col. 62, l. 54 - col. 96, l. 40; col. 96, l. 44 - col. 98, l. 37; col. 98, l. 41 - col. 99, l. 26; col. 99, l. 31 - col. 100, l. 39; col. 102, l. 51 - col. 105, l. 41; col. 113, l. 53 - col. 115, l. 12; Figs. 1-19.</p> <p><u>'223 patent</u>, col. 2, l. 3 - 18; col. 54, l. 7 - col. 55, l. 2; col. 56, l. 34 - col. 59, l. 38; col. 60, l. 1 - 13; col. 60, l. 15 - col. 61, l. 3; col. 61, l. 25 - col. 62, l. 8; col. 66, l. 14 - col. 99, l. 40; col. 99, l. 41 - col. 101, l. 17; col. 101, l. 21 - 67; col. 102, l. 1 - 67; col. 105, l. 1 - col. 108, l. 34</p> <p>Prosecution history of the '478 patent, including Application filed on May 20, 2015; Preliminary Amendment filed on June 3, 2015; Non-final Rejection dated June 8, 2015; Response after Non-final</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>Rejection dated August 14, 2015; Affidavit filed on August 14, 2015; Final Rejection dated October 22, 2015; Response after Final Rejection dated January 22, 2016; Affidavit filed on January 22, 2016; Non-final Rejection dated February 2, 2016; Response after Non-Final Rejection dated March 31, 2016; Affidavit filed on March 31, 2016; Notice of Allowance dated May 4, 2016; Issue Classification dated May 4, 2016</p> <p>Prosecution history of the '209 patent, including Application filed on February 7, 2017; Preliminary Amendment dated February 7, 2017; Non-final Rejection dated March 29, 2017; Response after Non-final Rejection dated June 28, 2017; Applicant-Initiated Interview Summary dated July 3, 2017; Notice of Allowance dated July 11, 2017; Issue Classification dated July 11, 2017</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					Prosecution history of the '239 patent, including Application filed on May 20, 2015; Preliminary Amendment filed on June 3, 2015; Non-final Rejection dated June 5, 2015; Response after Non-final Rejection dated August 14, 2015; Affidavit filed August 14, 2015; Final Rejection filed October 21, 2015; Response to Final Rejection filed November 24, 2015; Non-Final Rejection dated January 11, 2016; Examiner Initiated Interview Summary dated March 17, 2016; Applicant-Initiated Interview Summary dated March 17, 2016; Response to Non-Final Rejection filed on March 17, 2016; Affidavit filed March 17, 2016; Final Rejection filed May 12, 2016; Applicant-Initiated Interview Summary dated September 9, 2016; Response after Final Rejection filed on November 3, 2016; Non-final Rejection dated November 22, 2016; Response after Final Rejection filed on May 22, 2017; Affidavit filed May 22, 2017; Issue Classification dated July 11, 2017

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>Prosecution history of the '785 patent, including Application filed on February 7, 2017; Preliminary Amendment dated February 7, 2017; Non-final Rejection dated March 29, 2017; Response after Non-final Rejection dated June 28, 2017; Applicant-Initiated Interview Summary dated July 3, 2017; Notice of Allowance dated July 20, 2017; Issue Classification dated July 20, 2017</p> <p><u>Extrinsic Evidence:</u></p> <p>Sandoz may introduce testimony from one or more experts (e.g., Laird Forrest) regarding peptide formulation, the determination of peptide impurities in the relevant art, and/or how a person of ordinary skill in the art would have understood this claim term, namely that a person of ordinary skill would have understood the term to require a step of determining the impurities based on the HPLC method recited in the claim.</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					Sandoz reserves the right to introduce rebuttal testimony from one or more experts (e.g., Laird Forrest) in response to any expert testimony that Plaintiffs may introduce.
"consists essentially of"	'478 patent, claims 1-11	Ordinary meaning, no construction necessary (e.g., a unit dosage form that has the components and characteristics recited in the claim and may only include other materials that do not materially affect its stability, pharmaceutical acceptability, effectiveness in	MPEP § 2111.03 (Transitional Phrases) <i>E.g.</i> , '478 Patent, 1:18-41, 4:1-5:60, 7:22-51, 8:23-33, 11:3-12:16, 12:58-13:55; 15:41-24:21. Response to Final Office Action and Amendment (Appl. No. 14/717,882 ('478 Patent)), 7-12 (Mar. 31, 2016) – PAR-VASO-0002565-2579 Declaration of Vinayagam Kannan Appl. No. 14/717,882 ('478 Patent), (Mar. 31, 2016) – PAR-VASO-0002580-2590 Applicant-Initiated Interview Summary (Appl. No. 14/717,882	Indefinite	<u>Intrinsic Evidence:</u> '478 patent, claims 1 - 11 The specifications of the patents-in-suit, including the following passages: <u>'478 patent</u> , col. 1, l. 18 - 41; col. 4, l. 1 - col. 5, l. 60; col. 7, l. 22-51; col. 7, l. 53 - col. 8, l. 33; col. 11, l. 3 - col. 12, l. 16; col. 12, l. 58- col. 13, l. 55; col. 15, l. 41 - col. 24, l. 21; col. 24, l. 30 - col. 25, l. 3; col. 33, l. 1 - col. 34, l. 24 <u>'526 patent</u> , col. 1, l. 41 - 57; col. 12, l. 13 - 42; col. 102, l. 22 - 62

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
		treating hypotension, or suitability for intravenous injection)	('478 Patent)) (Mar. 18, 2016) – PAR-VASO-0002560-2563 Response to Final Office Action and Amendment (Appl. No. 14/717,882 ('478 Patent)), 2, 5-9 (Jan. 22, 2016) – PAR-VASO-0002283-2293 Declaration of Sunil Vandse (Appl. No. 14/717,882 ('478 Patent)), (Jan. 22, 2016) – PAR-VASO-0002304-2318 Response to Office Action and Amendment (Appl. No. 14/717,882 ('478 Patent)), 5-7 (Aug. 14, 2015) – PAR-VASO-0001039-1038 Declaration of Sunil Vandse (Appl. No. 14/717,882 ('478 Patent)),(Aug. 11, 2015) – PAR-VASO-0001039-1046 Par may additionally rely on expert opinion testimony to rebut any expert opinions proffered by Sandoz on this term.		'209 patent, col. 1, l. 44 - 58; col. 12, l. 14 - 43; col. 107, l. 44 - col. 108, l. 44 '239 patent, col. 1, l. 32 - 46; col. 8, l. 11 - 40; col. 25, l. 20 - col. 26, l. 1; col. 26, l. 19 - 28 '785 patent, col. 1, l. 40 - 54; col. 12, l. 13 - 42; col. 105, l. 48 - col. 106, l. 22; col. 106, l. 39 - 48 '223 patent, col. 1, l. 40 - 53; col. 13, l. 14 - 43; col. 129, l. 20 - col. 130, l. 1; col. 130, l. 19 - 28 Prosecution history of the '478 patent, including Application filed on May 20, 2015; Preliminary Amendment dated June 3, 2015; Non-final Rejection dated June 8, 2015; Response after Non-final Rejection dated August 14, 2015; Affidavit filed on August 14, 2015; Final Rejection dated October 22, 2015; Response after Final Rejection dated January 22, 2016; Affidavit filed on January 22, 2016; Non-final Rejection dated

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>February 2, 2016; Applicant-Initiated Interview Summary dated March 18, 2016; Response after Non-Final Rejection dated March 31, 2016; Affidavit filed on March 31, 2016; Notice of Allowance dated May 4, 2016; Notice of Allowance dated May 4, 2016; Issue Classification dated May 4, 2016</p> <p><u>Extrinsic Evidence:</u></p> <p>Plaintiff's Validity Contentions dated May 29, 2019 at 44.</p> <p>Plaintiffs' Disclosure of Asserted Claims and Initial Infringement Contentions Under Local Patent Rules 3.1 and 3.6 dated May 29, 2019 at Ex. A and G.</p> <p>Plaintiffs Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC's Responses and Objections to Defendant Sandoz Inc.'s Second Set of Interrogatories (No. 12) dated July 11, 2019</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>MPEP § 2111.03 (Transitional Phrases)</p> <p>Sandoz may introduce testimony from one or more experts (e.g., Laird Forrest, Michael Maile) regarding how a person of ordinary skill in the art would have understood this claim term, namely that a person of ordinary skill would have found that this term does not define the scope of the invention with reasonable certainty, including without limitation because the intrinsic evidence does not define the “basic and novel properties” of the alleged invention with reasonable certainty.</p> <p>Sandoz reserves the right to introduce rebuttal testimony from one or more experts (e.g., Laird Forrest, Michael Maile) in response to any expert testimony that Plaintiffs may introduce.</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
“wherein the human’s mean arterial blood pressure is increased within 15 minutes of administration”	'239 patent, claim 5 '478 patent, claim 3 '526 patent, claim 5	Ordinary meaning, no construction necessary <i>(e.g. wherein the mean arterial blood pressure of the human in need of having his or her blood pressure increased is increased within the first 15 minutes after the claimed vasopressin composition has been administered to him or her)</i>	'239 Patent 1:21-28, 2:1-32, 3:39-5:34, 22:17-25:13 (Example 8) '478 Patent 1:18-25, 2:16-44, 4:1-5:21, 21:22-24:23 (Example 8) '526 Patent 1:15-22, 2:35-65, 5:12-6:49, 13:28-45:59, 59:51-62:59 (Example 7) Par may additionally rely on expert opinion testimony to rebut any expert opinions proffered by Sandoz on this term.	This phrase is a non-limiting statement of intended result	<p><u>Intrinsic Evidence:</u></p> '478 patent, claims 1, 3 '526 patent, claims 1, 5 '239 patent, claims 1, 5 The specifications of the patents-in-suit, including the following passages: <u>'478 patent</u> , col. 1, l. 18 - 25; col. 2, l. 16 - 44; col. 4, l. 1 - col. 5, l. 21; col. 21, l. 22 - col. 24, l. 23; col. 33, l. 2-17; col. 33, l. 20 - 22 <u>'526 patent</u> , col. 1, l. 15 - 22; col. 2, l. 35 - 65; col. 5, l. 12 - col. 6, l. 49; col. 13, l. 28 - col. 45, l. 59; col. 59, l. 51 - col. 62, l. 59; col. 109, l. 64 - col. 111, l. 11; col. 111, l. 21 - 23 <u>'209 patent</u> , col. 1, l. 19 - 25; col. 2, l. 39 - 65; col. 4, l. 42 - col. 5, l. 67; col. 60, l. 17 - 20; col. 62, l. 16 - col. 63, l. 7 <u>'239 patent</u> , col. 1, l. 21 - 28; col. 2, l. 1 - 32; col. 3, l. 39 - col. 5, l. 34;

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>col. 22, l. 17 - col. 25, l. 13; col. 33, l. 31 - 53; col. 33, l. 65 - 67</p> <p><u>'785 patent</u>, col. 1, l. 15 - 21; col. 2, l. 38 - 65; col. 4, l. 43 - col. 5, l. 67; col. 59, l. 44 - 47; col. 61, l. 45 - col. 62, l. 39</p> <p><u>'223 patent</u>, col. 1, l. 16 - 22; col. 2, l. 57 - col. 3, l. 15; col. 5, l. 23 - col. 6, l. 67; col. 62, l. 34 - 37; col. 64, l. 40 - col. 65, l. 37; col. 128, l. 7 - col. 129, l. 2</p> <p>Prosecution history of the '478 patent, including Application filed on May 20, 2015; Preliminary Amendment dated June 3, 2015; Non-final Rejection dated June 8, 2015; Response after Non-final Rejection dated August 14, 2015; Final Rejection dated October 22, 2015; Response after Final Rejection dated January 22, 2016; Non-final Rejection dated February 2, 2016; Response after Non-Final Rejection dated March 31, 2016; Notice of Allowance dated May 4, 2016;</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>Issue Classification dated May 4, 2016</p> <p>Prosecution history of the '239 patent, including Application filed on May 20, 2015; Preliminary Amendment dated June 3, 2015; Non-final Rejection dated June 5, 2015; Response after Non-final Rejection dated August 14, 2015; Final Rejection filed October 21, 2015; Response to Final Rejection filed November 24, 2015; Non-Final Rejection dated January 11, 2016; Examiner Initiated Interview Summary dated March 17, 2016; Applicant-Initiated Interview Summary dated March 17, 2016; Response to Non-Final Rejection filed on March 17, 2016; Affidavit filed March 17, 2016; Final Rejection filed May 12, 2016; Applicant-Initiated Interview Summary dated September 9, 2016; Response after Final Rejection filed on November 3, 2016; Non-final Rejection dated November 22, 2016; Response after Final Rejection filed on May 22, 2017;</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>Issue Classification dated July 11, 2017</p> <p>Prosecution history of the '526 patent, including Application filed on October 10, 2016; Preliminary Amendment dated October 10, 2016; Non-final Rejection dated February 22, 2017; Applicant-Initiated Interview Summary dated April 11, 2017; Response after Non-final Rejection dated May 2, 2017; Notice of Allowance dated May 12, 2017; Issue Classification dated May 12, 2016</p> <p>T. Treschan et al., The Vasopressin System Physiology and Clinical Strategies, <i>Anesthesiology</i> (2006) 105:599-612. (SAND-VASO00007208-7221)</p> <p>M.L. Buck, Low-dose Vasopressin Infusions for Vasodilatory Shock, <i>Pediatric Pharmacotherapy</i> (2003) 9(9): 1-4. (SAND-VASO00006921-6924)</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>M. Argenziano et al., A Prospective Randomized Trial of Arginine Vasopressin in the Treatment of Vasodilatory Shock After left Ventricular Assist Device Placement, <i>Circulation</i> (1997) 96(9): II-286-II-290. (SAND-VASO00006735-6743)</p> <p>D.L.S. Morales et al., Arginine Vasopressin in the Treatment of 50 Patients With Postcardiotomy Vasodilatory Shock, <i>Ann. Thorac. Surg.</i> (2000) 69:102-106. (SAND-VASO00007078-7082)</p> <p>D.W. Landry et al., Vasopressin Deficiency Contributes to the Vasodilation of Septic Shock, <i>Circulation</i> (1997) 95(5): 1122-1125. (SAND-VASO00008090-8098)</p> <p>Vasostrict (vasopressin injection) for intravenous use dated April 2014. (SAND-VASO00007231-7239)</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					<p>Vasostrict (vasopressin injection) for intravenous use dated September 2014. (SAND-VASO00007240-7243)</p> <p>Vasostrict (vasopressin injection) for intravenous use dated March 2016. (SAND-VASO00007247-7248)</p> <p>Vasostrict (vasopressin injection) for intravenous use dated December 2016. (SAND-VASO00007249-7250)</p> <p><u>Extrinsic Evidence:</u></p> <p>Sandoz may introduce testimony from one or more experts (e.g., Michael Maile) regarding the clinical effects of administering vasopressin and/or how a person of ordinary skill in the art would have understood this claim term, namely that a person of ordinary skill would have understood the term to recite an intended result of the claimed method and not to further limit the claimed method.</p>

Term for Construction	Claims	Par's Proposed Construction	Par's Supporting Evidence	Sandoz's Proposed Construction	Sandoz's Supporting Evidence
					Sandoz reserves the right to introduce rebuttal testimony from one or more experts (e.g., Michael Maile) in response to any expert testimony that Plaintiffs may introduce.